Keyphrases
Neutralizing Antibodies
100%
Interferon-β (IFN-β)
76%
Multiple Sclerosis
53%
Interferon-α (IFN-α)
46%
Relapsing-remitting multiple Sclerosis
42%
Interferon-β Treatment
32%
Interferon beta-1a
32%
Binding Antibodies
27%
Clinical Significance
21%
Severe Complications
16%
Multiple Sclerosis Treatment
16%
Recombinant Human
16%
Liver Transplantation
16%
Standardized Incidence Ratio
16%
Enzyme-linked Immunosorbent Assay (ELISA)
16%
Population-based Study
16%
CD26
16%
Bioactivity
16%
Laparoscopic Cholecystectomy
16%
Gallstones
16%
Cancer Incidence
16%
Dose Rate
16%
Treatment Effect
16%
Autoantibodies
16%
Immunogenicity
16%
Interferon alpha-2b
16%
Age-related Macular Degeneration
16%
CD4 Count
16%
Route of Administration
16%
Immunology and Microbiology
Beta Interferon
80%
Neutralizing Antibody
65%
Multiple Sclerosis
53%
Binding Antibody
26%
Relapsing Remitting Multiple Sclerosis
26%
Interferon
24%
CD4 Lymphocyte Count
16%
Enzyme Immunoassay
16%
Cytokine
16%
Interferon Beta 1b
16%
Alpha2a Interferon
16%
Biological Activity
16%
Interferon Beta 1a
16%
Immunogenicity
16%
Interferon Alfa
16%
Autoantibody
16%
Magnetic Resonance Imaging
16%
Pharmacology, Toxicology and Pharmaceutical Science
Beta Interferon
65%
Multiple Sclerosis
53%
Neutralizing Antibody
49%
Immunogenicity
16%
Standardized Incidence Ratio
16%
Route of Administration
16%
Gallstone
16%
Beta1a Interferon
16%
Malignant Neoplasm
16%
